Clinical trial NCT00136994: IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study)
Official title: An Open Trial to Evaluate the Efficacy and Tolerability of Ziprasidone IM and Oral in Patients With Psychosis and Acute Agitation.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Schizophrenia
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2005-08-29
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate efficacy and tolerability of Ziprasidone IM and oral in agitated patients with acute exacerbation of schizophrenia


Eligibility criteria: Inclusion Criteria:

* Psychiatric:
* Diagnosis of schizophrenia using DSM-IV (295.xx).
* Patients entering hospital (or inpatients transferring to higher-dependency unit) within the previous seven days because of acute exacerbation of psychotic symptoms.
* PANSS \> 80 (score Â³ 3 on at least three of the following PANSS agitation items: anxiety , tension, hostility, excitement).
* CGI-S Â³ 4. - Indication, based on intensity/severity of psychotic symptoms, on IM therapy.
* General:
* Male or Female patients aged 18-60 years at screening.
* Written informed consent to participation.
* Female patients of at risk of pregnancy must avoid to remain pregnant; an adequate method of contraception can be initiated or continued.

Exclusion Criteria:

* Psychiatric:
* Patients at immediate risk of committing harm to self or others
* Concurrent treatment with other antipsychotic agents after baseline
* Patients receiving depot antipsychotic medication within 21 days of screening
* Treatment with antidepressants or mood stabilizers (such as lithium, carbamazepine, valproic acid or verapamil) within two weeks of screening
* Diagnosis of substance abuse using DSM-IV criteria within previous 12 months
* Positive urine drug screen at screening for amphetamine, cocaine or opioids
* Alcohol and/or any other drug abuse at screening
* Patients who have received clozapine within 3 months prior to screening due to intolerance to other antipsychotics or patients who have received clozapine in the past two years for refractoriness to treatment
* Treatment with any investigational agent within the previous six months
* Previous treatment with ziprasidone
* Organic mental disease, including mental retardation
* History of psychosurgery
* General:
* Patients with a history of clinically significant and/or currently relevant hematological, renal (including single kidney), hepatic, gastrointestinal, endocrine (except for current adequately treated hypo- or hyperthyroidism), pulmonary (excluding chronic bronchitis, mild emphysema or chronic obstructive pulmonary disease), dermatological, oncological, or neurological disease, excluding tardive dyskinesia but including all forms of epilepsy (febrile convulsions in childhood acceptable). The only patients with known prior malignant disease who are eligible are those with cured prior skin cancer (excluding melanoma). Controlled Type II diabetes (glucose \< 180 mg/100 ml at screening and baseline with dietary or oral hypoglycemic treatment) will not be considered a significant medical illness and would not exclude a subject from the study - Patients with a history of significant cardiovascular disease or significant concurrent cardiovascular disease, including a history of uncontrolled hypertension (supine diastolic pressure \>95 mm Hg and/or supine systolic pressure \> 170 mm Hg with or without treatment)
* Clinically significant ECG abnormality
* Patient with QTc Â³ 450 msec - Concomitant treatment with medications that prolong QT interval
* Patients with serum K+ or Mg++ outside the normal range
* Confirmed clinically significant laboratory values.
* Known serological evidence of HIV, or acute or chronic hepatitis (with transaminase levels higher than three times the normal limits)
* Patients who intend to donate blood or blood products during the 4 weeks prior to the study, during the study or in the 30 days after the study ends
* Patients unable or unlikely to follow the study protocol
* Pregnant or lactating women
* Patients with a history of neuroleptic malignant syndrome developing from the administration of antipsychotic compounds
* Known hypersensitivity to ziprasidone or lactose

Primary outcomes:
measure: To evaluate efficacy and tolerability of Ziprasidone IM and oral in agitated patients with acute exacerbation of schizophrenia
Secondary outcomes:
Other outcomes:
Locations:
city: Savigliano
country: Italy
facility: Pfizer Investigational Site
state: Cuneo
city: Campi Bisenzio
country: Italy
facility: Pfizer Investigational Site
state: Firenze
city: Sora
country: Italy
facility: Pfizer Investigational Site
state: Frosinone
city: Parma
country: Italy
facility: Pfizer Investigational Site
state: PR
city: S. Arsenio
country: Italy
facility: Pfizer Investigational Site
state: Salerno
city: Bologna
country: Italy
facility: Pfizer Investigational Site
city: Cagliari
country: Italy
facility: Pfizer Investigational Site
city: Caserta
country: Italy
facility: Pfizer Investigational Site
city: Chiari (BS)
country: Italy
facility: Pfizer Investigational Site
city: Cremona
country: Italy
facility: Pfizer Investigational Site
city: Fidenza(pr)
country: Italy
facility: Pfizer Investigational Site
city: Foggia
country: Italy
facility: Pfizer Investigational Site
city: Genova-sestri
country: Italy
facility: Pfizer Investigational Site
city: Genova
country: Italy
facility: Pfizer Investigational Site
city: Lecce
country: Italy
facility: Pfizer Investigational Site
city: Milano
country: Italy
facility: Pfizer Investigational Site
city: Modena
country: Italy
facility: Pfizer Investigational Site
city: Moncalieri(to)
country: Italy
facility: Pfizer Investigational Site
city: Napoli
country: Italy
facility: Pfizer Investigational Site
city: Noto
country: Italy
facility: Pfizer Investigational Site
city: Orbassano (to)
country: Italy
facility: Pfizer Investigational Site
city: Padova
country: Italy
facility: Pfizer Investigational Site
city: Palermo
country: Italy
facility: Pfizer Investigational Site
city: Perugia
country: Italy
facility: Pfizer Investigational Site
city: Pordenone
country: Italy
facility: Pfizer Investigational Site
city: Roma
country: Italy
facility: Pfizer Investigational Site
city: Sassari
country: Italy
facility: Pfizer Investigational Site
city: Senigallia (AN)
country: Italy
facility: Pfizer Investigational Site
city: Torino
country: Italy
facility: Pfizer Investigational Site
city: Torino
country: Italy
facility: Pfizer Investigational Site
city: Torrette DI Ancona (AN)
country: Italy
facility: Pfizer Investigational Site
city: Udine
country: Italy
facility: Pfizer Investigational Site
city: Verona
country: Italy
facility: Pfizer Investigational Site
city: Viareggio
country: Italy
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References: